Search results

1

Deep molecular response (MR4.5) as a target of therapy with tyrosine kinase inhibitors. MR4.5 – goal of CML treatment

100%

Sacha T.

OncoReview

|

2014

|

vol. 4

|

issue 1

A27-32

EN

Chronic myeloid leukemia (CML) accounts for 15% of diagnosed leukemias. The annual incidence in two Polish regions has been calculated for 0.7/100,000 of general population. Introduction of tyrosine kinase inhibitors (TKIs) have substantially improved not only the prognosis of CML, but also changed the treatment goals, and the expectations of patients and physicians. The goals of CML therapy include: to prevent the progression towards accelerated phase and blastic phase, to eliminate the risk of death from leukemia, to prolong the length of survival to comparable of healthy population and to attain a quality of life comparable to healthy people. Patients treated up-front with second generation TKIs (2GTKI) have a better chance to achieve faster and deeper response to therapy. Most of patients receiving 2GTKI in first line or e.g. nilotinib after initial phase of imatinib therapy can achieve very deep molecular response (MR4.5), which is a key criterion for discontinuation studies. The results of stop-trials suggest that substantial proportion of patient could achieve sustained treatment-free survival, and that the disease could be controlled despite of persistence of minimal residual disease, which does not require a clinical intervention. Patients group that could benefit most from discontinuation study include younger people, those who have achieved MR4.5 and patients reporting TKI – associated side effects. Achievement of MR4.5 could be considered as a target of CML therapy for considerable proportion of patients. The question of safe TKI dose reduction or therapy cessation should be addressed in the future planned clinical trials.

2

Patient with metastatic renal cell carcinoma treated successfully with pazopanib for four years.

100%

Słowik A., Streb J., Chrzan R., Krzemieniecki K.

OncoReview

|

2015

|

vol. 5

|

issue 3

A109-116

EN

We present a case of a patient with metastatic renal cell carcinoma who was treated with pazopanib in the first-line treatment. Although nephrectomy was not performed, there was a positive reaction to the therapy with multi-targeted tyrosine kinase inhibitor. After 18 months of the palliative treatment, the cancerous kidney was surgically removed and pazopanib was restarted with the effect of further disease remission. The development of hypertension, complete hair discoloration and isolated hyperbilirubinemia occurred, and there was occasionally hypokalaemia in laboratory findings within 48 months of therapy. No serious adverse events were reported.

3

The effect of tyrosine kinase inhibitors used in the treatment of chronic myeloid leukemia on the cardiovascular system

100%

Sacha T., Góra-Tybor J., Szmit S.

OncoReview

|

2019

|

vol. 9

|

issue 1

3-21

EN

The use of tyrosine kinase inhibitors (TKIs) in the treatment of chronic myeloid leukemia has significantly improved the prognosis and outcomes for most patients. Clinical trials indicate that long-term CML therapy requires the introduction of second- or third-generation inhibitors in approximately 40–50% of cases. Effective in the case of imatinib resistance or intolerance, second generation TKI’s can also be used as a first-line treatment, leading to a faster, and deeper molecular response. TKIs, however, have also been observed to cause significant late adverse effects, including cardiovascular complications, which may raise certain safety concerns. The excellent treatment outcomes achieved with tyrosine kinase inhibitors have led to a gradual increase in the number and age of treated patients, and the associated higher incidence and severity of age-related co-morbidities such as diabetes, hypercholesterolemia, atherosclerosis, ischemic heart disease, hypertension, and congestive heart failure, which raise the risk of treatment-related cardiovascular complications. The article discusses the effects of individual TKIs on the pathogenesis of cardiovascular complications and presents the results of clinical trials that studied their impact on the incidence of such events.

4

Advances in hematology – research that revolutionized patient care

63%

Wach M., Podhorecka M., Cioch M., Hus I., Wąsik-Szczepanek E., Sokołowska B., Hus M.

|

issue 1

32-35

EN

In the last decades, substantial strides have been made in the diagnosis, treatment, and prevention of blood diseases. The new drugs to be used in combination with cytostatic therapy have been developed, based on increased understanding of the biology of neoplasia. The diagnosis of several diseases is based exclusively on cytogenetic and molecular analysis which has become a part of routine diagnostic management. Moreover, molecular definition has allowed the introduction of therapy targeted at molecular change characteristic for a given disease. The introduction of novel agents for the treatment of hematological disorders has resulted in a great improvement in response rate and median survival. The aim of this study is to show advances and possible future directions in the treatment of chosen hematological malignancies during the recent decades.

Refine search results

3 OncoReview

1 Polish Journal of Public Health

1 2019

2 2015

1 2014

2 Sacha T.

1 Chrzan R.

1 Cioch M.

1 Góra-Tybor J.

1 Hus I.

1 Hus M.

1 Krzemieniecki K.

1 Podhorecka M.

1 Sokołowska B.

1 Streb J.

1 Szmit S.

1 Słowik A.

1 Wach M.

1 Wąsik-Szczepanek E.

Deep molecular response (MR4.5) as a target of therapy with tyrosine kinase inhibitors. MR4.5 – goal of CML treatment

Patient with metastatic renal cell carcinoma treated successfully with pazopanib for four years.

The effect of tyrosine kinase inhibitors used in the treatment of chronic myeloid leukemia on the cardiovascular system

Advances in hematology – research that revolutionized patient care